InvestorsHub Logo
Post# of 4973165
Next 10
Followers 39
Posts 7318
Boards Moderated 0
Alias Born 10/17/2013

Re: None

Tuesday, 11/15/2022 11:04:47 AM

Tuesday, November 15, 2022 11:04:47 AM

Post# of 4973165
NEOVACS (ALNEV) : 0.014
52w: 0.0135 - 14.0000
Chemical/Pharmaceutical/Health
ISIN: FR00140077X1

Neovacs SA is a France-based company active in the biotechnology industry. It specializes in immunotherapy domain and providing treatment for autoimmune and inflammatory diseases. The Company researches and develops Kinoids, drug-candidates which aim to treat disease by including an antibody response in the patient. The Company focuses its development effort on two Kinoids for Crohn’s disease, Rheumatoid Arthritis and lupus disease. Neovacs SA’s portfolio of products includes TNF-Kinoids, IFN-Kinoids and VEGF-Kinoids. The Company operates in France and the United States. In May 2016, the Company signed a joint venture agreement with Stellar Biotechnologies Inc to create Neostell, owned by the Company in 70%.

https://www.neovacs.com/fr/ (no Englisch update)

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.